Carumonam

Carumonam
Clinical data
Trade names	Amasulin
AHFS/Drugs.com	International Drug Names
ATC code	J01DF02 (WHO) ;
Identifiers
	IUPAC name 2-[(Z)-[1-(2-Amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid;
CAS Number	87638-04-8 ;
PubChem CID	6540466;
DrugBank	DB13553 ;
ChemSpider	5022832 ;
UNII	486890PI06;
ChEBI	CHEBI:55486;
ChEMBL	ChEMBL1614658 ;
CompTox Dashboard (EPA)	DTXSID3048312 ;
Chemical and physical data
Formula	C12H14N6O10S2
Molar mass	466.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=C(N=C(S1)N)/C(=N/OCC(=O)O)/C(=O)N[C@H]2[C@H](N(C2=O)S(=O)(=O)O)COC(=O)N;
	InChI InChI=1S/C12H14N6O10S2/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26)/b17-7-/t5-,8+/m1/s1 ; Key:UIMOJFJSJSIGLV-JNHMLNOCSA-N ;
	(what is this?) (verify)

Carumonam (INN) is a monobactam antibiotic^[1] previously sold in Japan under the brand name Amasulin.^[2] One of only four members of its class,^[3] Carumonam was withdrawn sometime before 2021,^[4] leaving only Aztreonam on the market. It is very resistant to beta-lactamases, which means that it is more difficult for bacteria to break down using β-lactamase enzymes.^[5]

References

↑ McNulty CA, Garden GM, Ashby J, Wise R (September 1985). "Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam". Antimicrobial Agents and Chemotherapy. 28 (3): 425–7. doi:10.1128/aac.28.3.425. PMC 180266. PMID 4073864.
↑ Hara, Takuji (1997). "Industrial Technological Trajectories and Corporate Technology Traditions : The Development of Antibacterial Drugs in Japan". The Annals of the School of Business Administration, Kobe University. 41: 1–18. doi:10.24546/81003680.
↑ "Monobactam Derivative - an overview". ScienceDirect. Elsevier. Retrieved 4 August 2026.
↑ "ATC/DDD Index 2026: Carumonam (J01DF02)". WHO Collaborating Centre for Drug Statistics Methodology. 15 December 2011. Retrieved 4 August 2026.
↑ PubChem. "Carumonam". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-12-08.

[1] McNulty CA, Garden GM, Ashby J, Wise R (September 1985). "Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam". Antimicrobial Agents and Chemotherapy. 28 (3): 425–7. doi:10.1128/aac.28.3.425. PMC 180266. PMID 4073864.

[2] Hara, Takuji (1997). "Industrial Technological Trajectories and Corporate Technology Traditions : The Development of Antibacterial Drugs in Japan". The Annals of the School of Business Administration, Kobe University. 41: 1–18. doi:10.24546/81003680.

[3] "Monobactam Derivative - an overview". ScienceDirect. Elsevier. Retrieved 4 August 2026.

[4] "ATC/DDD Index 2026: Carumonam (J01DF02)". WHO Collaborating Centre for Drug Statistics Methodology. 15 December 2011. Retrieved 4 August 2026.

[5] PubChem. "Carumonam". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-12-08.

[1]

[2]

[3]

[4]

[5]